Bob McDonnell headed back to court Thursday over federal corruption charges alleging that he and...
Pluristem Therapeutics has announced that it has completed the approval process and received...
The Galien Foundation today announced the 2014 nominees for the eighth annual Prix Galien USA....
Astellas has appointed Moyra Knight as the head of corporate and employee communications in the Americas region. Knight will report directly to Jeff Winton, senior vice president, chief communications officer.
Meda announced today that it has entered into a definitive agreement to acquire Rottapharm/Madaus, an Italian company owned by the Rovati family, for a consideration of SEK 21.2 billion on a cash and debt free basis.
Sanofi said today its earnings soared in the second quarter thanks to lower accounting charges than a year earlier, and the company lifted it full-year profit forecast.
Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the company’s board of directors.
Facing ballooning costs for a $1,000 pill to treat hepatitis C, Illinois' Medicaid program is putting tight restrictions in place, including requiring patients to meet 25 criteria and get prior approval before the government program will pay for the new drug.
There has always been much hand-wringing and shouting regarding the costs of new medications. Most of this comes from people outside the industry – politicians, public health advocates, and a smattering of those that just like to hear themselves talk.
McKesson Corporation today announced a three-year extension of its existing distribution agreement with CVS Caremark through June, 2019.
AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.
Packaging Coordinators has reached a definitive agreement to acquire Penn Pharmaceutical Services Limited. Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom and operates regional offices in New Hope, Pennsylvania and Tokyo, Japan.
AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones.
Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.
Amgen said it will lay off 12 to 15 percent of its worldwide workforce and close four sites, even as it reported stellar second-quarter results that trounced Wall Street expectations.
Shares of Impax Labs sank Tuesday after an FDA inspection uncovered potential problems at a facility where the company will make its experimental Parkinson's disease drug Rytary.
ISPE has hired John Bournas as President and CEO, succeeding Nancy Berg who announced plans to leave the Society last fall. Mr. Bournas takes the helm at ISPE with extensive competencies in the healthcare association industry as well as significant international experience.
Fitch Ratings expects that revenues from biologic therapies as a percentage of total pharmaceutical sales will continue to increase over the intermediate term as companies increase their prominence in their drug portfolios, according to a report published today.
Getting relief from a slowdown in health care spending, the program's giant hospital trust fund won't be exhausted until 2030, the government said Monday. That's four years later than last year's estimate.
Idaho prison officials say they had to have thousands of dollars' worth of medications shipped overnight to the state's largest prison after the former operator, Corrections Corporation of America, left the facility without a promised eight-day supply of inmate drugs.
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.
In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health. But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66B.
The Corning, New York-based company said earnings fell to $169 million, or 11 cents per share, from $638 million, or 43 cents per share, in the same quarter a year ago.
Merck has reported earnings that more than doubled in its second quarter, and topped analysts' expectations. The Whitehouse Station, New Jersey-based company said net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.
A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland.
Ortho-Clinical Diagnostics has entered into a strategic partnership with Astute Medical, under which OCD will become the exclusive commercial partner for the distribution of Astute’s NEPHROCHECK ® Test and ASTUTE140 ® Meter in certain markets in Europe and, pending FDA clearance, the United States.
- Page 1